Fust Matthew K sold (to issuer) $2.4M of CRNX
Fust Matthew K sold (to issuer) 28,761 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($2.44M total) across 2 trades on 2026-09-01.
How this was made
The 30-second read
Why it matters
The director's complete exit may be interpreted as a lack of confidence, influencing traders.
Market read
Insider sale of $2.44M in a micro‑cap biotech could trigger short‑term price pressure.
What to watch
Potential upcoming financing needs or personal tax planning.
Background
SEC Form 4 filing discloses insider transactions for public companies.
Ticker impact
Director Matthew Fust sold 28,761 shares for $2.44M, reducing his stake to zero.
Potential short-term dip of 1‑2% as market digests the sale.
A $2.4M sale by a director is material for a micro‑cap biotech and often leads to modest price weakness.
Market effects
May raise concerns for other small‑cap biotech stocks with insider sales.
Limited to US biotech sector.
Low global impact.
Counterpoint
The sale could be a routine liquidity event, not a negative signal.
Key entities
- CompanyCrinetics Pharmaceuticals, Inc.
Biopharmaceutical company developing treatments for rare diseases.
- InsiderMatthew Fust
Director of Crinetics who sold his entire shareholding.
